| Medical and Health Sciences | Lifetime | 61 | SE 1 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 17 | SE 1 | 100.00 |
| Biological Sciences | 2021-2025 | 354 | SE 2 | 99.63 |
| Medical Physiology | Lifetime | 3 | SE 1 | 100.00 |
| Psychiatry and Mental health | Lifetime | 22 | SE 1 | 99.94 |
| Clinical Neurology | Lifetime | 75 | SE 3 | 99.74 |
| Neuroscience of Neurology | Lifetime | 61 | SE 1 | 99.48 |
| Epidemiology | Lifetime | 738 | SE 6 | 99.02 |
| Cellular and Molecular Neuroscience | Lifetime | 576 | SE 23 | 97.73 |
| Pathology and Forensic Medicine | Lifetime | 658 | SE 14 | 97.04 |
| Emergency Medicine | Lifetime | 595 | SE 15 | 94.28 |
| Rheumatology | Lifetime | 979 | SE 25 | 94.03 |
| Critical Care and Intensive Care Medicine | Lifetime | 351 | SE 7 | 92.46 |
| Biological Psychiatry | Lifetime | 136 | SE 1 | 90.98 |
| Medical Physiology | 2021-2025 | 1 | SE 1 | 99.99 |
| Psychiatry and Mental health | 2021-2025 | 1 | SE 1 | 99.98 |
| Clinical Neurology | 2021-2025 | 20 | SE 2 | 99.50 |
| Neuroscience of Neurology | 2021-2025 | 30 | SE 1 | 98.38 |
| Cellular and Molecular Neuroscience | 2021-2025 | 64 | SE 4 | 95.06 |
| Molecular Biology | 2021-2025 | 630 | SE 5 | 96.59 |
| Epidemiology | 2021-2025 | 454 | SE 6 | 96.10 |
| Pathology and Forensic Medicine | 2021-2025 | 230 | SE 3 | 93.26 |
| Public, Environmental and Occupational Health | 2021-2025 | 849 | SE 14 | 91.37 |
| Critical Care and Intensive Care Medicine | 2021-2025 | 105 | SE 2 | 89.96 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 478 | SE 4 | 90.39 |
| Cognitive Neuroscience | 2021-2025 | 514 | SE 6 | 90.23 |
| Rheumatology | 2021-2025 | 365 | SE 11 | 86.01 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 746 | SE 14 | 82.07 |
| Alzheimer's disease research and treatments | Lifetime | 2 | SE 1 | 99.99 |
| Dementia and Cognitive Impairment Research | Lifetime | 2 | SE 1 | 99.99 |
| S100 Proteins and Annexins | Lifetime | 1 | SE 1 | 99.95 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 2 | SE 1 | 99.96 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 9 | SE 2 | 99.81 |
| Traumatic Brain Injury and Neurovascular Disturbances | Lifetime | 34 | SE 3 | 99.82 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 15 | SE 3 | 99.79 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 32 | SE 2 | 99.84 |
| Computational Drug Discovery Methods | Lifetime | 57 | SE 1 | 99.46 |
| Health, Environment, Cognitive Aging | Lifetime | 16 | SE 2 | 99.52 |
| Traumatic Brain Injury Research | Lifetime | 28 | SE 2 | 99.52 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 30 | SE 2 | 99.36 |
| Cardiac Arrest and Resuscitation | Lifetime | 180 | SE 7 | 99.38 |
| Cerebrospinal fluid and hydrocephalus | Lifetime | 68 | SE 3 | 99.04 |
| Metabolomics and Mass Spectrometry Studies | Lifetime | 140 | SE 3 | 98.94 |
| Tryptophan and brain disorders | Lifetime | 121 | SE 1 | 99.22 |
| Folate and B Vitamins Research | Lifetime | 114 | SE 5 | 98.42 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 176 | SE 3 | 99.38 |
| Functional Brain Connectivity Studies | Lifetime | 201 | SE 3 | 99.45 |
| Advanced Neuroimaging Techniques and Applications | Lifetime | 154 | SE 3 | 99.18 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 162 | SE 4 | 98.99 |
| Amyotrophic Lateral Sclerosis Research | Lifetime | 85 | SE 3 | 98.77 |
| Diet and metabolism studies | Lifetime | 808 | SE 30 | 98.62 |
| Prion Diseases and Protein Misfolding | Lifetime | 90 | SE 1 | 98.27 |
| Cerebrovascular and genetic disorders | Lifetime | 44 | SE 2 | 97.77 |
| Intracerebral and Subarachnoid Hemorrhage Research | Lifetime | 318 | SE 3 | 97.65 |
| Neurological diseases and metabolism | Lifetime | 198 | SE 3 | 97.39 |
| Multiple Sclerosis Research Studies | Lifetime | 421 | SE 12 | 97.46 |
| Ginkgo biloba and Cashew Applications | Lifetime | 88 | SE 1 | 96.19 |
| Advanced Proteomics Techniques and Applications | Lifetime | 430 | SE 12 | 95.94 |
| Epilepsy research and treatment | Lifetime | 954 | SE 15 | 96.55 |
| Anesthesia and Neurotoxicity Research | Lifetime | 785 | SE 26 | 95.81 |
| Amino Acid Enzymes and Metabolism | Lifetime | 824 | SE 17 | 95.50 |
| Bioinformatics and Genomic Networks | Lifetime | 716 | SE 8 | 95.47 |
| Bipolar Disorder and Treatment | Lifetime | 758 | SE 9 | 96.05 |
| Genetic Associations and Epidemiology | Lifetime | 970 | SE 19 | 95.42 |
| Nuclear Receptors and Signaling | Lifetime | 476 | SE 13 | 93.96 |
| Neurological and metabolic disorders | Lifetime | 471 | SE 10 | 92.18 |
| Skin and Cellular Biology Research | Lifetime | 796 | SE 12 | 91.98 |
| Inflammation biomarkers and pathways | Lifetime | 268 | SE 4 | 86.77 |
| Cancer-related cognitive impairment studies | Lifetime | 788 | SE 13 | 86.48 |
| Studies on Chitinases and Chitosanases | Lifetime | 733 | SE 10 | 83.48 |
| GDF15 and Related Biomarkers | Lifetime | 806 | SE 31 | 75.76 |
| Clusterin in disease pathology | Lifetime | 281 | SE 7 | 74.52 |
| Biological Research and Disease Studies | Lifetime | 107 | SE 3 | 67.73 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 1 | SE 1 | 100.00 |
| Alzheimer's disease research and treatments | 2021-2025 | 1 | SE 1 | 99.99 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 12 | SE 1 | 99.58 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 5 | SE 1 | 99.32 |
| S100 Proteins and Annexins | 2021-2025 | 3 | SE 1 | 98.87 |
| Health, Environment, Cognitive Aging | 2021-2025 | 10 | SE 1 | 98.43 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 43 | SE 2 | 99.05 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 9 | SE 1 | 96.54 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 62 | SE 2 | 98.57 |
| Diet and metabolism studies | 2021-2025 | 169 | SE 4 | 97.95 |
| Advanced Neuroimaging Techniques and Applications | 2021-2025 | 119 | SE 2 | 97.05 |
| Traumatic Brain Injury Research | 2021-2025 | 75 | SE 2 | 96.94 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 45 | SE 1 | 95.91 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 187 | SE 5 | 97.46 |
| Tryptophan and brain disorders | 2021-2025 | 164 | SE 1 | 96.09 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 65 | SE 1 | 97.29 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 90 | SE 3 | 96.08 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 78 | SE 2 | 93.59 |
| Functional Brain Connectivity Studies | 2021-2025 | 444 | SE 7 | 96.10 |
| Long-Term Effects of COVID-19 | 2021-2025 | 690 | SE 10 | 94.53 |
| Neuroscience and Neuropharmacology Research | 2021-2025 | 276 | SE 4 | 94.99 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 403 | SE 15 | 96.05 |
| Folate and B Vitamins Research | 2021-2025 | 76 | SE 5 | 91.69 |
| Epilepsy research and treatment | 2021-2025 | 338 | SE 5 | 94.14 |
| Genetic Associations and Epidemiology | 2021-2025 | 466 | SE 9 | 91.73 |
| Multiple Sclerosis Research Studies | 2021-2025 | 362 | SE 12 | 94.20 |
| Cancer-related cognitive impairment studies | 2021-2025 | 142 | SE 4 | 89.41 |
| Cerebrospinal fluid and hydrocephalus | 2021-2025 | 332 | SE 15 | 89.08 |
| Nutritional Studies and Diet | 2021-2025 | 984 | SE 21 | 90.63 |
| Bipolar Disorder and Treatment | 2021-2025 | 398 | SE 14 | 89.61 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 871 | SE 13 | 87.08 |
| Frailty in Older Adults | 2021-2025 | 919 | SE 20 | 88.12 |
| Anesthesia and Sedative Agents | 2021-2025 | 500 | SE 1 | 83.72 |
| Prion Diseases and Protein Misfolding | 2021-2025 | 136 | SE 3 | 85.08 |
| Intracerebral and Subarachnoid Hemorrhage Research | 2021-2025 | 709 | SE 5 | 83.30 |
| Skin and Cellular Biology Research | 2021-2025 | 173 | SE 2 | 81.24 |
| Neurological diseases and metabolism | 2021-2025 | 253 | SE 4 | 80.94 |
| Memory and Neural Mechanisms | 2021-2025 | 640 | SE 2 | 79.34 |
| Neonatal and fetal brain pathology | 2021-2025 | 946 | SE 25 | 80.51 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 977 | SE 8 | 79.09 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 834 | SE 12 | 79.05 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 851 | SE 15 | 81.24 |
| Neurological Complications and Syndromes | 2021-2025 | 241 | SE 3 | 75.83 |
| Spinal Dysraphism and Malformations | 2021-2025 | 451 | SE 9 | 73.06 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 242 | SE 4 | 69.17 |
| Polyomavirus and related diseases | 2021-2025 | 797 | SE 20 | 73.33 |
| Thermal Regulation in Medicine | 2021-2025 | 398 | SE 15 | 70.79 |
| Fetal and Pediatric Neurological Disorders | 2021-2025 | 740 | SE 8 | 73.55 |
| GDF15 and Related Biomarkers | 2021-2025 | 272 | SE 15 | 69.82 |
| Neurological and metabolic disorders | 2021-2025 | 202 | SE 5 | 71.57 |
| Inflammation biomarkers and pathways | 2021-2025 | 131 | SE 2 | 68.85 |
| Nuclear Receptors and Signaling | 2021-2025 | 441 | SE 7 | 63.75 |
| Down syndrome and intellectual disability research | 2021-2025 | 394 | SE 7 | 66.65 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 203 | SE 4 | 62.18 |
| Genetic Syndromes and Imprinting | 2021-2025 | 896 | SE 9 | 61.78 |
| Cerebrovascular and genetic disorders | 2021-2025 | 315 | SE 4 | 60.96 |
| Hereditary Neurological Disorders | 2021-2025 | 839 | SE 7 | 57.33 |
| Menopause: Health Impacts and Treatments | 2021-2025 | 701 | SE 12 | 54.94 |
| Ginkgo biloba and Cashew Applications | 2021-2025 | 652 | SE 4 | 43.47 |
| Cognitive Functions and Memory | 2021-2025 | 931 | SE 13 | 20.05 |